Burzynski Research Institute (BZYR) Change in Accured Expenses (2010 - 2025)
Burzynski Research Institute (BZYR) posted Change in Accured Expenses of -$22452.0 for Q4 2025, down 1699.15% sequentially from $1404.0 in Q3 2025, and down 192.0% YoY from $24403.9 in Q4 2024.
Burzynski Research Institute (BZYR) Change in Accured Expenses (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported Change in Accured Expenses for 16 years, with the latest figure at -$22452.0 in Q4 2025.
- Quarterly Change in Accured Expenses fell 192.0% year-over-year to -$22452.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $20249.0 (up 274.73% YoY) and the FY2025 annual result came in at $7044.0, down 54.06% from the prior year.
- Change in Accured Expenses fell to -$22452.0 in Q4 2025 per BZYR's latest filing, from $1404.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $45518.0 in Q2 2023 and troughed at -$46313.0 in Q3 2024.
- A 5-year average of $635.5 and a median of $1947.0 in 2021 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1641.67% in 2021, down 506.35% in 2021.
- Over 5 years, Change in Accured Expenses stood at -$10411.0 in 2021, then soared by 84.64% to -$1599.0 in 2022, then jumped by 698.75% to $9574.0 in 2023, then tumbled by 180.31% to -$7689.0 in 2024, then sank by 192.0% to -$22452.0 in 2025.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered -$22452.0, $1404.0, and $20088.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -22,452.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -22,452.00 |
| Nov 30, 2025 | -22,452.00 |
| Aug 31, 2025 | 1,404.00 |
| Aug 31, 2025 | 1,404.00 |
| May 31, 2025 | 20,088.00 |
| May 31, 2025 | 20,088.00 |
| Feb 28, 2025 | 21,209.00 |
| Feb 28, 2025 | 21,209.00 |
| Nov 30, 2024 | -7,689.00 |
| Nov 30, 2024 | -7,689.00 |
| Aug 31, 2024 | -46,313.00 |
| Aug 31, 2024 | -46,313.00 |
| May 31, 2024 | 39,837.00 |
| May 31, 2024 | 39,837.00 |
| Feb 29, 2024 | 2,576.00 |
| Feb 29, 2024 | 2,576.00 |
| Nov 30, 2023 | 9,574.00 |
| Nov 30, 2023 | 9,574.00 |
| Aug 31, 2023 | -42,336.00 |
| Aug 31, 2023 | -42,336.00 |